New research trials surrounding the medication Retatrutide , specifically the 120 milligram formulation ZPHC ZPHC, suggest a considerable impact on weight loss and related metabolic illnesses . Researchers posit that this dual agonist , affecting both GLP-1 and GIP receptors , may offer a major